CIDRAP newsletters options
Shortages of some drugs to treat kids' respiratory illnesses come amid surges of RSV and the flu and continuing COVID-19.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
Originally published by CIDRAP News Dec 1
The US Food and Drug Administration (FDA) announced yesterday that it has approved a fecal microbiota product for the prevention of recurrent Clostridioides difficile infection (CDI) in adults.
The study highlights a likely high rate of asymptomatic disease spread.
As hospitalizations almost double, most states are experiencing high or very high flu levels.
Antibiotic use on European farms has fallen 43.2%, compared with 30.4% in the US.
Given CWD's incubation period, it's possible the case is connected to a 2021 finding at an illegal dump site.
Commercial farms in Missouri, South Dakota, Illinois, and Maryland were hit in the most recent outbreaks.
"It is clear that ... healthcare services and policy need to prioritise long Covid care."
The Democratic Republic of the Congo, Indonesia, and Yemen reported polio cases.
Data reflect about an 11% incidence of residual lung damage known as interstitial lung disease after COVID-19 hospitalization.
Attending classes online was more stressful than in-person or hybrid instruction.
Africa CDC said African countries are seeing a replay of COVID-19 vaccine deployment.
COVID-19 infection is tied to increased liver stiffness, a sign of possible long-term liver injury.
Approval of Rebyota, made by Ferring Pharmaceuticals, was based on findings from multiple randomized clinical trials.
Over half of those who had COVID-19 in 2020 reported persistent long-COVID symptoms and continued use of health services.
The first locations for the expanded surveillance involve Michigan and Philadelphia.
Omicron appears to have similar risk of long-COVID symptoms as the Delta variant.
Nearly 2.7 million COVID-19 cases were reported to the WHO last week, up 2% from the week before.
The drug was 95% effective 18 months after treatment for sleeping sickness in adults and teens, regardless of disease stage.
Global flu activity rose in the first half of November, mainly due to rising levels in North America and parts of Europe.
